Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
19.97
+0.02 (0.10%)
Aug 21, 2025, 4:00 PM - Market closed
Innoviva Employees
Innoviva had 127 employees as of December 31, 2024. The number of employees increased by 15 or 13.39% compared to the previous year.
Employees
127
Change (1Y)
15
Growth (1Y)
13.39%
Revenue / Employee
$2,915,189
Profits / Employee
$304,323
Market Cap
1.26B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 127 | 15 | 13.39% |
| Dec 31, 2023 | 112 | 11 | 10.89% |
| Dec 31, 2022 | 101 | 96 | 1,920.00% |
| Dec 31, 2021 | 5 | 0 | - |
| Dec 31, 2020 | 5 | -1 | -16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INVA News
- 8 days ago - Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award - Business Wire
- 15 days ago - Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress - Business Wire
- 2 months ago - FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 - Business Wire
- 2 months ago - Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults - Business Wire
- 2 months ago - Innoviva to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections - Business Wire
- 3 months ago - Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States - GlobeNewsWire
- 3 months ago - Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress - Business Wire